Torrent Pharma Allots 4.19 Cr Shares in J.B. Chemicals Amalgamation
Torrent Pharmaceuticals allotted 4,19,22,416 equity shares to J.B. Chemicals shareholders on July 20, 2026, as part of their amalgamation scheme. The share exchange ratio is 51 Torrent Pharma shares for every 100 J.B. Chemicals shares. This increases Torrent Pharma's paid-up capital to ₹1,90,18,39,280.
The amalgamation and subsequent share allotment will alter the company's capital structure and potentially lead to operational synergies, impacting its financial standing and market presence.
The announcement details the successful allotment of shares as part of a significant amalgamation, indicating progress and completion of a key corporate action.
Torrent Pharmaceuticals Limited has announced the allotment of 4,19,22,416 fully paid-up equity shares of face value ₹5 each to the eligible shareholders of J. B. Chemicals & Pharmaceuticals Limited. This allotment, approved by the Securities Transfer and Stakeholders Relationship Committee on July 20, 2026, is in accordance with the Scheme of Amalgamation of J. B. Chemicals with Torrent Pharmaceuticals.
The record date for this allotment was July 17, 2026. The share exchange ratio stipulated in the Scheme is 51 fully paid-up equity shares of Torrent Pharma (face value ₹5) for every 100 fully paid-up equity shares of J. B. Chemicals (face value ₹1).
Following this allotment, Torrent Pharmaceuticals' issued and paid-up equity share capital has increased from ₹1,69,22,27,200 (representing 33,84,45,440 equity shares of ₹5 each) to ₹1,90,18,39,280 (representing 38,03,67,856 equity shares of ₹5 each). The newly allotted equity shares will rank pari passu with the existing equity shares of Torrent Pharmaceuticals in all respects.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.